Luven Diagnostic

Luven Diagnostic

Created using Figma
推广独特的癌症诊断技术。
数据不可用
ICO
2018年1月15日
2018年2月28日
100% 完成
$26 350
100% 目标 完成
past
  • 290 LVN
    =
    1 ETH
Pre-ICO
2017年12月8日
2017年12月29日
100% 完成
募集资金 - 无数据
past
  • 290 LVN
    =
    1 ETH
令牌详细信息
断续器
LVN
接受的货币
ETH, BTC
公司详情
注册国家
Ukraine
额外细节
平台
Ethereum
分类
健康

关于 Luven Diagnostic

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.

The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.

For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.

Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.

According to statistics:

  • after treatment in stage 1 cancer — around 93% of patients survive;
  • stage 2 cancer — around 75% survive;
  • stage 3 cancer — 55% survive;
  • stage 4 cancer — only 13% survive;

This is why one should get a check-up as often as possible, thus preventing the disease progression.

Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.

The key to successful cancer treatment is early diagnosis.

Our History

The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the development of LUVEN a unique diagnostic and treatment system. As of today, this method allowed to collect statistical data on tests of more than twenty thousand of patients.

Why is it lucrative?

Cancer research is an acute social problem, in view of this they cast a veil on profits of medical companies. However, in-vitro diagnostics, and particularly cancer diagnostics, is a huge and most rapidly developing sector, with the potential global market of DNA cancer tests worth about $20 bn.

Unlike the majority of projects involving ICO, our company has already completed 90% of the whole thing. The presale period starts on November 15 until December 6, 2017. The token sale is planned from January 15 to February 28, 2018.

特征

  • 已完成项目的90%。

代币持有者有两个机会:

  • 收到部分公司收入
  • 交换他们的代币用于测试服务,其中30% 折扣,使用或销售给批发客户

技术信息

以太坊ERC20标准令牌。

%name%Roadmap

  • 1983

  • Development ofthe cancer diagnostic method started, based on the study of buccal cells (cells from the inside ofthe cheek)
  • 2004年

  • 细胞形态生物学诊断方法的出现,形成了诊断复合体的基础
  • 2010

  • Team expansion. A commercial enterprise promoting the LUVEN trademark was established. The software automating a part ofthe diagnostic procedure was created.
  • 2014

  • 在“第五届国际医学论坛”和“2014年医疗保健”两大国际医疗展览会上,该诊断方法获得专利,完成临床试验,创建软件诊断综合体。开设第一家专营店。
  • 阅读更多
  • 2015年

  • 在特许经营后的五个月内,合同签订了二十多个网点,其中一半已经对二千多个病人进行了测试。暂停活动一段时间,使技术提高。
  • 2016年至2017年

  • 软件增强,额外的临床试验。优化大量的系统算法
  • 2017年9月至10月

  • 准备和启动一个preICO,旨在为项目的软件增强,法律成本和运营支出筹集资金
  • 2018年1月

  • 开始一个ICO
  • 2018

  • 进一步提高软件质量,与世界各地的临床医疗机构签署合同,在奥地利开设研究中心。在欧盟和欧亚联盟启动该方法的认证
  • 2019

  • 在欧盟和欧亚联盟开设了20个新的实验室,包括一个区块链和一个国内交易所,用于销售令牌,对细胞传入图像进行光学识别,创建一个病人数据库和监测倾向的测试结果,并通知患者对被诊断的必要性
  • 2020

  • 在美国和亚洲开始临床试验和认证
  • 2021

  • 开发家庭小工具(家庭实验室),随时启动整个家庭的测试,启动产品。

Luven Diagnostic 球队

验证 0%

注意。未经证实的成员实际上可能不是团队成员

Alexander Danilchenk...
CEO
未验证
Nikolay Shchukin
Postgraduate Student of Chair for Biomedical Engin...
未验证
Aleksander Shchukin
Nuclear Physician
未验证
Galina Shchukina
Geneticist & Cytologist
未验证
Grigory Evglevskiy
CTO
未验证
Alexander Kamensky
Principal Software Engineer
未验证
Yana Ivchenko
PR Manager
未验证

Luven Diagnostic 最新消息

  • 由于信息更新可能存在时间差异,因此应通过其官方网站或其他沟通渠道验证有关每个ICO项目的准确信息。
  • 这些信息不是投资ICO资金的建议或建议。请自行彻底调查相关信息并决定ICO的参与情况。
  • 如果您认为有任何问题需要纠正,或者您想提交自己的ICO项目,请给我们发送电子邮件。
请阅读免责声明和风险警告。 显示免责声明和风险警告。